Desmarais LLP earned recognition as a finalist in five categories for the 2025 LMG Life Sciences Americas Awards, including Firm of the Year (Intellectual Property), General Patent Litigation Firm of the Year, Intellectual Property Boutique Firm of the Year, and partner John Desmarais as Appellate Litigator of the Year (Intellectual Property) and General Patent Litigator of the Year (New York). This is the seventh straight year that Desmarais LLP has been shortlisted for the LMG Life Sciences Americas Awards.
Among its recent life sciences victories, Desmarais LLP secured three wins before the Federal Circuit upholding the patents behind $429.5 million in damages won in the district courts for Ravgen’s non-invasive prenatal genetic testing technology. In a separate matter before the International Trade Commission, the firm earned a successful administrative law judge ruling in a section 337 trade secret case involving Botox products that found Croma-Pharma committed no violation. The Commission later affirmed the judge’s decision.
The 2025 LMG Life Sciences Americas Awards honor the industry’s top firms and practitioners across four key practice areas – regulatory, intellectual property, financial and corporate, and non-IP litigation and enforcement. As part of their annual review process, researchers assess firms based on casework, feedback from industry peers, and responses provided by clients. Judges then select the leading firms and practitioners as finalists, highlighting their achievements during the last 12 months. LMG Life Sciences will recognize the 2025 winners at an event on September 4 in New York City.
See the LMG Life Sciences Americas Awards shortlist
Desmarais LLP Named Leading Patent Litigation Firm in IP Stars Rankings, 11 Partners Recognized
Accolades
Managing IP highlighted Desmarais LLP in its 2025 IP Stars rankings. Among other rankings, the Firm earned a distinction as a Tier 1 firm for in “Patent Disputes” (National). This...
MORE